Cargando…

Confirmed 6-Month Disability Improvement and Worsening Correlate with Long-term Disability Outcomes in Alemtuzumab-Treated Patients with Multiple Sclerosis: Post Hoc Analysis of the CARE-MS Studies

INTRODUCTION: In the 2-year CARE-MS trials (NCT00530348; NCT00548405) in patients with relapsing–remitting multiple sclerosis, alemtuzumab showed superior efficacy versus subcutaneous interferon beta-1a. Efficacy was maintained in two consecutive extensions (NCT00930553; NCT02255656). This post hoc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hunter, Samuel F., Aburashed, Rany A., Alroughani, Raed, Chan, Andrew, Dive, Dominique, Eichau, Sara, Kantor, Daniel, Kim, Ho Jin, Lycke, Jan, Macdonell, Richard A. L., Pozzilli, Carlo, Scott, Thomas, Sharrack, Basil, Wiendl, Heinz, Chung, Luke, Daizadeh, Nadia, Baker, Darren P., Vermersch, Patrick
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8571457/ https://www.ncbi.nlm.nih.gov/pubmed/34165694 http://dx.doi.org/10.1007/s40120-021-00262-3

Ejemplares similares

Efficacy of alemtuzumab in relapsing-remitting MS patients who received additional courses after the initial two courses: Pooled analysis of the CARE-MS, extension, and TOPAZ studies
por: Comi, Giancarlo, et al.
Publicado: (2019)

Efficacy of alemtuzumab over 6 years in relapsing–remitting multiple sclerosis patients who relapsed between courses 1 and 2: Post hoc analysis of the CARE-MS studies
por: Van Wijmeersch, Bart, et al.
Publicado: (2019)

Lymphocyte pharmacodynamics are not associated with autoimmunity or efficacy after alemtuzumab
por: Wiendl, Heinz, et al.
Publicado: (2019)

Predictors of disability worsening in clinically isolated syndrome
por: Jokubaitis, Vilija G, et al.
Publicado: (2015)

Confirmed disability progression as a marker of permanent disability in multiple sclerosis
por: Sharmin, Sifat, et al.
Publicado: (2022)

Efficacy and Safety of Alemtuzumab Through 9 Years of Follow-up in Patients with Highly Active Disease: Post Hoc Analysis of CARE-MS I and II Patients in the TOPAZ Extension Study
por: Ziemssen, Tjalf, et al.
Publicado: (2020)

Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients
por: Giovannoni, Gavin, et al.
Publicado: (2016)

A matter of atrophy: differential impact of brain and spine damage on disability worsening in multiple sclerosis
por: Ruggieri, Serena, et al.
Publicado: (2021)

The FTO gene polymorphism rs9939609 is associated with obesity and disability in multiple sclerosis patients
por: Al-Serri, Ahmad, et al.
Publicado: (2019)

Long-term efficacy of alemtuzumab in polymyositis
por: Ruck, Tobias, et al.
Publicado: (2015)

Alemtuzumab in Multiple Sclerosis: Mechanism of Action and Beyond
por: Ruck, Tobias, et al.
Publicado: (2015)

Measuring disability in multiple sclerosis: the WHODAS 2.0
por: Young, Carolyn A., et al.
Publicado: (2023)

The use of alemtuzumab in patients with relapsing-remitting multiple sclerosis: the Gulf perspective
por: Alroughani, Raed, et al.
Publicado: (2020)

Dalfampridine improves slowed processing speed in multiple sclerosis patients with mild motor disability: post hoc analysis of a randomized controlled trial
por: Pozzilli, Carlo, et al.
Publicado: (2021)

Cortical fractal dimension predicts disability worsening in Multiple Sclerosis patients
por: Roura, Eloy, et al.
Publicado: (2021)

Overall Disability Response Score: An integrated endpoint to assess disability improvement and worsening over time in patients with multiple sclerosis
por: Chang, Ih, et al.
Publicado: (2022)

Deep gray matter volume loss drives disability worsening in multiple sclerosis
por: Eshaghi, Arman, et al.
Publicado: (2018)

Gut microbiome composition is associated with long-term disability worsening in multiple sclerosis
por: Devolder, Lindsay, et al.
Publicado: (2023)

Alemtuzumab
por: Tridente, Giuseppe
Publicado: (2013)

Predicting the profile of increasing disability in multiple sclerosis
por: Tomassini, Valentina, et al.
Publicado: (2018)

Wearable sensors can reliably quantify gait alterations associated with disability in people with progressive multiple sclerosis in a clinical setting
por: Angelini, Lorenza, et al.
Publicado: (2020)

Greater sensitivity to multiple sclerosis disability worsening and progression events using a roving versus a fixed reference value in a prospective cohort study
por: Kappos, Ludwig, et al.
Publicado: (2017)

pRNFL as a marker of disability worsening in the medium/long term in patients with MS
por: Cordano, Christian, et al.
Publicado: (2018)

Long-Term Consequences of Worsened Poststroke Status in Patients With Premorbid Disability: Implications for Treatment
por: Ganesh, Aravind, et al.
Publicado: (2018)

Disability worsening among persons with multiple sclerosis and depression: A Swedish cohort study
por: Binzer, Stefanie, et al.
Publicado: (2019)

Safety of Alemtuzumab and Autologous Hematopoietic Stem Cell Transplantation Compared to Noninduction Therapies for Multiple Sclerosis
por: Alping, Peter, et al.
Publicado: (2021)

Pharmacological Approaches to Delaying Disability Progression in Patients with Multiple Sclerosis
por: Wiendl, Heinz, et al.
Publicado: (2015)

Quality of Life Improves with Alemtuzumab Over 6 Years in Relapsing-Remitting Multiple Sclerosis Patients with or without Autoimmune Thyroid Adverse Events: Post Hoc Analysis of the CARE-MS Studies
por: Bertolotto, Antonio, et al.
Publicado: (2020)

Alemtuzumab therapy changes immunoglobulin levels in peripheral blood and CSF
por: Möhn, Nora, et al.
Publicado: (2019)

Brain atrophy and disability worsening in primary progressive multiple sclerosis: insights from the INFORMS study
por: Miller, David H., et al.
Publicado: (2018)

Heart rate variability is differentially altered in multiple sclerosis: implications for acute, worsening and progressive disability
por: Studer, Valeria, et al.
Publicado: (2017)

Does a modifiable risk factor score predict disability worsening in people with multiple sclerosis?
por: Marck, Claudia H, et al.
Publicado: (2019)

Predicting disability progression and cognitive worsening in multiple sclerosis using patterns of grey matter volumes
por: Colato, Elisa, et al.
Publicado: (2021)

Occurrence and Severity of Coronavirus Disease 2019 Are Associated With Clinical Disability Worsening in Patients With Multiple Sclerosis
por: Peeters, Gertjan, et al.
Publicado: (2023)

Management of adverse renal events related to alemtuzumab treatment in multiple sclerosis: a Belgian consensus
por: Sprangers, Ben, et al.
Publicado: (2017)

Differences in HIV knowledge and sexual practices of learners with intellectual disabilities and non-disabled learners in Nigeria
por: Aderemi, Toyin J, et al.
Publicado: (2013)

Autoimmunity and long-term safety and efficacy of alemtuzumab for multiple sclerosis: Benefit/risk following review of trial and post-marketing data
por: Coles, Alasdair J, et al.
Publicado: (2021)

Contribution of Relapse-Independent Progression vs Relapse-Associated Worsening to Overall Confirmed Disability Accumulation in Typical Relapsing Multiple Sclerosis in a Pooled Analysis of 2 Randomized Clinical Trials
por: Kappos, Ludwig, et al.
Publicado: (2020)

Social participation in patients with multiple sclerosis: correlations between disability and economic burden
por: Kwiatkowski, Arnaud, et al.
Publicado: (2014)

Ensemble machine learning identifies genetic loci associated with future worsening of disability in people with multiple sclerosis
por: Fuh-Ngwa, Valery, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_pub0flfb75hveck89fv7bdr4pv